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Background: There is much concern regarding undisclosed corporate authorship (“ghostwriting”) in the
peer-reviewed medical literature. However, there are no studies of how disclosure of ghostwriting alone impacts
the perceived credibility of research results.
Findings: We conducted a randomized vignette study with experienced nurses (n = 67), using a fictional study of
antidepressant medication. The vignette described a randomized controlled trial and gave efficacy and adverse
effect rates. Participants were randomly assigned to one of two authorship conditions, either (a) traditional
authorship (n = 35) or (b) ghostwritten paper (n = 32), and then completed a perceived credibility scale. Our
primary hypothesis was that the median perceived credibility score total would be lower in the group assigned to
the ghostwritten paper. Our secondary hypotheses were that participants randomized to the ghostwritten
condition would be less likely to (a) recommend the medication, and (b) want the psychiatrist in the vignette as
their own clinician. We also asked respondents to estimate efficacy and adverse effect rates for the medication.
There was a statistically significant difference in perceived credibility among those assigned to the ghostwriting
condition. This amounted to a difference of 9.0 points on the 35-point perceived credibility scale as tested through
the Mann–Whitney U test. There was no statistically significant difference between groups in terms of
recommending the medication, wanting the featured clinician as their own, or in estimates of efficacy or adverse
effects (p > .05 for all such comparisons).
Conclusion: In this study, disclosure of ghostwriting resulted in lower perceived credibility ratings.Findings
Background
There is much concern regarding conflicts-of-interest
[1,2] and authorship within the peer-reviewed medical
literature, particularly in pharmaceutical industry-funded
randomized controlled trials of therapeutics [3-7]. This
has largely been sparked by a growing body of evidence
from medico-legal cases demonstrating the prevalence
of “ghostwriting,” [8] an undisclosed conflict-of-interest
in which a pharmaceutical company employee or sub-
contractor co-authors a study but is not listed on the* Correspondence: jeffrey.lacasse@asu.edu
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reproduction in any medium, provided the orauthorship byline [9]. It is now common for evidence of
ghostwriting to be available on the internet for widely
used blockbuster medications [10-12]. Increasingly, clini-
cians are likely to encounter revelations of ghostwriting
for established treatments both within medical journals
[11-14] and in the general media, such as the New York
Times [15,16].
As reported in both a prominent randomized controlled
trial and a recent systematic review of the literature, finan-
cial conflicts-of-interest (COIs) are known to reduce the
perceived credibility of research [17,18]. However, little is
known regarding how practicing clinicians perceive ghost-
written research. To our knowledge, there has been only
one study directly related to this issue [19]. This was a
study of 50 hospital-based clinicians randomly assigned tol Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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thor had a financial COI and in which the article had been
ghostwritten, and the other in which there was no COI
and traditional authorship. The research results in the
COI group were much less believed by clinicians (Cohen’s
d = 1.4), suggesting that disclosure of relatively common
COIs had a clinically significant impact on their view of
the research. The major limitation of the study was that
the COI conditions were bundled (there was no “ghost-
writing only” condition) so that the impact of financial
COI or ghostwriting could not be identified separately.
We therefore conducted a follow-up study examining the
impact of ghostwriting alone on perceived credibility.
Methods
Two vignettes modified slightly from the original study
were used [19]. Both vignettes contained an identical de-
scription of a fictional study of a new antidepressant (“Ser-
ovux”) for adult use. The vignettes described the study
sample, methods, and results; the conclusion claimed that
Serovux was a safe and effective treatment, utilizing lan-
guage from a well-known antidepressant study [10,20].
One vignette described the research as having been ghost-
written (ghostwriting condition), while the other described
traditional academic authorship (non-ghostwriting condi-
tion). Other than modifying the reported COI and chan-
ging the clinical population from children to adults, no
major changes were made to the vignettes used in the ori-
ginal experiment. We opted not to change vignette con-
tent substantially because we had found evidence of face
validity in our earlier study; ghostwriting experts agreed
that these vignettes described a ghostwriting incident
“similar to those known to have occurred in real life” and
agreed that a clinician reading the scientific literature
would be “likely to come across studies that were gener-
ated in a manner similar to that described” [19]. The vign-
ettes are available as Additional files (see Additional file 1:
Vignette 1.pdf and Additional file 2: Vignette 2.pdf).
Our primary outcome measure was perceived credibil-
ity of the results, measured through a 7-item Likert scale
that asked respondents to rate how truthful, accurate,
credible, honest and sincere the research vignette was.
Although this scale has not been formally validated in
terms of psychometrics, it was derived from items within
the existing perceived credibility instrument literature,
and this instrument was found to be reliable (Cronbach’s
alpha = 0.95) in a previous study [19]. We measured two
types of secondary outcomes. First, two dichotomous
questions answered in a yes/no format, [1] “If I was hav-
ing problems with depression, I would like to have Dr.
Harvey [The name of the psychiatrist featured in the vi-
gnette] as my psychiatrist” and “If a friend you cared
about was severely depressed, would you recommend
Serovux?”. Second, we asked respondents to estimate thepercentage of patients who (a) benefitted significantly
from Serovux, and (b) had significant side effects from
Serovux.
Our primary hypothesis was that the median perceived
credibility score total would be lower in the group
assigned to the ghostwriting condition. Our secondary
hypotheses were that participants randomized to the
ghostwritten condition would be less likely to (a) recom-
mend the medication, and (b) want the psychiatrist in
the vignette as their own clinician. We also speculated
that when asked to estimated efficacy and adverse effect
rates, participants in the ghostwriting group would dis-
count the reported rate of efficacy and inflate the
reported rate of adverse effects.
We performed power analysis using G*Power 3.04
[21]. Guided by our previous results, we calculated that
we needed 35 participants per group to detect a large
difference in perceived credibility (Cohen’s d = 0.8)
with 95% power. Data analysis was performed using
PASW version 18.0 (SPSS, Inc, Chicago, IL, USA) and
Minitab version 15.1.0.0 (Mini-tab Inc., State College,
Pennsylvania, USA). Our data analysis strategy con-
sisted of comparing total credibility scores by group
using the Mann–Whitney U test, appropriate for use
with ordinal data that is not normally distributed, as
well as contingency table analysis for the dichotomous
variables. Given our small sample size, 95% confidence
intervals were to be reported to define the precision of
our point estimates. Secondarily, we also planned to
describe mean total credibility scores across groups and
calculate effect size in the form of Cohen’s d.
Participants were recruited from two sources. First,
data were collected from students in a graduate-level
nurse practitioner course taking place at a large South-
western University in a major metropolitan area. Using
a random number generator (www.random.org), the se-
quence of the printed vignettes and attached instru-
mentation was randomized, which were then handed
out to students in the classroom setting. The re-
searcher distributing the materials was blind to their
content (i.e., he did not know which vignette was dis-
tributed to each nurse). All students in the class were
invited to voluntarily participate. Second, an invitation
to take an on-line version of the survey was distributed
to community nurses though a local email listerv. The
survey was placed online using SurveyGizmo survey
software, and randomization was automated. The title
of the project was “Perceptions of Biomedical Research”
and participants were not aware that the goal of the
project was to examine the impact of ghostwriting on
perceived credibility. Institutional review board ap-
proval was granted by the Arizona State University
Office of Research Integrity and Assurance, and each
participant provided informed consent.
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Sixty-seven nurses participated in this study, meaning
that our study was underpowered according to our pre-
study power analysis. Fifty-seven of the sixty-one nurses
registered for the course participated in this study, for a
response rate of 93.44%. We did not track whether the
nursing students who did not participate (n = 4) refused
participation or were simply not in attendance for that
class session. An additional ten nurses completed the
online version of the survey.
There were no missing data for the perceived cred-
ibility items. The Cronbach’s alpha for the perceived
credibility scale used in the present study was 0.91. A
principal components analysis (PCA) extracted only
one component thus establishing that our 5-question
credibility scale was a unidimensional measure of cred-
ibility. The two questions which asked about the effi-
cacy/side effect rate of Serovux had 7.5% and 9.0%
missing data, respectively, while the remaining variables
all had minimal missing data (<5%). Given the small
amount of missing data, we performed complete-case
analyses [22].
The majority of participants were female, Caucasian,
and were experienced clinicians (see Table 1). Respon-
dents randomized to the non-ghostwriting vignette had
a mean credibility score of 22.00 ±5.87, while those
assigned to the ghostwriting vignette had a mean cred-
ibility score of 15.37 ±7.85. This results in a difference in
perceived credibility of 6.63 points, a Cohen’s d of 0.96.
Since the data did not meet the assumption of normality
necessary for parametric tests and the credibility scale is
ordinal, we tested the difference using the Mann–Whitney
U statistic [23]. This resulted in a difference between med-
ians of 9.0 points (95% CI = 4.0 - 12.0; see Table 2).
There were no statistically significant differences
across groups on any of the remaining variables. Respon-
dents randomized to the ghostwriting condition were
less likely to want the psychiatrist in the vignette as their
own clinician (OR = 0.34, 95% CI = 0.10 - 1.24), or toTable 1 Participant demographics by vignette group*
Characteristic Non-Ghostwriting
Vignette (n = 35)
Ghostwriting
Vignette (n = 32)
Age, years† 36.97 ± 11.26 36.00 ± 10.25
Female gender, No. (%) 35 (100) 30 (93.75)
Caucasian, No. (%) 24 (68.57) 24 (75.0)
Bachelors in Nursing, No. (%)‡ 23 (65.71) 26 (81.25)
Clinical experience, years† 12.51 ± 9.82 11.04 ± 9.84
Clinical experience in mental
health, years†
7.26 ± 10.12 6.31 ± 9.42
* Does not include cases with missing data (2 cases for race/ethnicity, 1 case
for clinical experience, and 3 cases for clinical experience in mental health).
† Values are presented as means ± Standard Deviation.
‡ Refers to highest degree earned.recommend the antidepressant (“Serovux”) featured in
the vignette (OR = 0.44, 95% CI = 0.13 - 1.49), but these
results were not statistically significant. The mean esti-
mated efficacy rate for Serovux was 53.53% ±14.12 in
the non-ghostwriting condition and 47.50% ±24.59 in
the ghostwriting condition, and the mean estimated side
effect rate was 11.85% ±7.86 in the non-ghostwriting
condition and 13.24% ±10.65 in the ghostwriting condi-
tion, with identical median values across both vignette
conditions (p > .05 for all these comparisons).
We had combined two subsamples for analysis, nurses
taking a graduate-level class (n = 57) and nurses partici-
pating in a local email listserv for community nurses (n =
10). As a separate analysis, we excluded the nurses
reached through the email listserv (n = 10) and re-
analyzed the data. The results were essentially the same
(i.e., <0.5 points difference in overall perceived credibility
ratings).
Discussion
Experienced nurses (n = 67) who read a fictional anti-
depressant study found the vignette less credible when
informed that the research was ghostwritten. The differ-
ence was statistically significant (p < .001), consisting of
a 9-point difference (95% CI, 4.00 -12.00) between med-
ians on a 35-point scale. There was a difference of 6.63
points in mean scores, corresponding to a Cohen’s d of
0.96. By normal social science standards, this is consid-
ered a large effect size [24]. To our knowledge, this is
the first published study to find an impact of ghost-
writing alone on perceived credibility.
This finding has several potential implications. The
previous study [19] used vignettes reporting a pediatric
antidepressant study, raising the possibility that respon-
dents were reacting to the issue of pediatric psychiatric
prescribing, a controversial issue in some quarters. The
present study reached similar findings while reporting
an adult antidepressant study, suggesting that the results
of these studies are not dependent on the population
described. These results also may inform the ongoing
debate regarding the ability of clinicians to engage in
evidence-based practice within an environment of less-
than-ideal transparency in authorship, selective reporting
of data, and so forth. In short, activities such as ghost-
writing and selective reporting have ramifications down-
stream for the clinicians who rely on such data to
practice ethically and scientifically [25-28]. Although this
is somewhat speculative, the large effect size found in
this study could be interpreted as indicating that prac-
ticing clinicians consider ghost authorship an important
issue worthy of attention and regulation. Finally, legal
scholars are now exploring the issue of ghostwriting,
and our findings may have ramifications for this body of
literature as well [29,30].
Table 2 Credibility ratings by ghostwriting condition
Outcome Variable No Ghostwriting (n = 35) Ghostwriting (n = 32) P-value* Difference of Medians
(95% CI)*Mean ± SD Median Mean ± SD Median
Truthful 4.54 ±1.25 5.00 3.28 ±1.78 3.00 .003
Accurate 4.23 ±1.21 4.00 3.72 ±1.76 3.50 .144
Credible 4.14 ±1.26 4.00 2.84 ±1.78 2.50 .001
Honest 4.46 ±1.42 4.00 2.53 ±1.90 2.00 <.001
Sincere 4.63 ±1.37 5.00 3.00 ±1.95 2.00 <.001
Overall Credibility Scale Total† 22.00 ±5.87 23.00 15.37 ±7.85 13.00 <.001 9.00 (4.00 – 12.00)
*As calculated using the Mann–Whitney U test.
† Out of an achievable scale total of 35 points.
Lacasse et al. BMC Research Notes 2012, 5:490 Page 4 of 6
http://www.biomedcentral.com/1756-0500/5/490However, our finding that disclosure of ghostwriting is
associated with lower perceived credibility also raises
many questions that cannot be answered by the present
study. As suggested by two anonymous reviewers, these
include: Why do the nurses perceive ghostwritten re-
search as less credible? Are nurses aware of the pro-
blems that ghostwriting presents to the integrity of
science, or are they reacting to some other factor? Is the
primary issue the challenge to evidence-based medicine,
a reaction to a deceptive practice, or hostility to the
pharmaceutical industry? Are nurses aware of the Inter-
national Committee of Medical Journal Editors (ICMJE)
authorship standards, which were violated in this study?
Is it reasonable to expect any seasoned health profes-
sional to form an opinion of a medication or clinician
based on one short vignette? These are all research
questions worthy of further research, and many are
probably best addressed through qualitative inquiry.
After completing two research studies on ghostwriting,
one potential explanation for the finding of reduced
credibility has emerged, albeit subjectively, anecdotally,
and speculatively. During our data collection, we
encountered anecdotal evidence suggesting that prac-
ticing clinicians are not generally aware of the practice
of ghostwriting (e.g., from written comments on the in-
strumentation and verbal comments spoken to the
investigators as subjects returned their instruments). If
this is broadly true, a portion of the reduced credibility
may be due to a disconnect between how clinicians envi-
sion research and authorship and the process described
in the ghostwriting vignette condition. Future investiga-
tions on this topic might consider this hypothesis.
Although the nurses in our study found ghostwritten
research less credible, the other variables we examined
had smaller effect sizes. Subjects randomized to the
ghostwriting condition were less likely to want the
psychiatrist in the vignette as their own clinician or to
recommend the antidepressant for a depressed friend,
but this difference was not statistically significant. This
is partially a result of low statistical power for these vari-
ables, as we powered the study to examine our primaryoutcome, which we assumed had a large effect size.
However, there were other nuances in these data. For
both of these questions, only 10/34 (29.41%) participants
in the non-ghostwriting group endorsed the psychiatrist
and antidepressant portrayed in the vignette. We con-
sider this a low level of endorsement given that the non-
ghostwriting vignette presented a rigorous clinical trial
similar to many well-cited reports of real-world anti-
depressant research. This skepticism may reflect growing
public dissatisfaction with the pharmaceutical industry
[31], knowledge of the contemporary debate regarding
antidepressant medications [32-35], or unknown factors.
However, these findings are also suggestive of the
complexities involved in moving from perceived credibil-
ity (a fairly straightforward outcome measure) to deci-
sion making. Although subjects randomized to the
ghostwriting condition had lower credibility scores, they
did not substantially discount the efficacy of the medica-
tion nor inflate the rate of adverse effects. In other
words, they found the ghostwritten study less credible;
but when asked to act or report on the data given to
them, many arguably answered as if they did indeed be-
lieve the results. This may reflect defensive decision
making on the part of prescribers [36], or the use of
heuristics [37] in decision making.
Our study has several limitations that should shape in-
terpretation of the results. Most of the nurses in the
study were pursuing an advanced degree and thus may
not be representative of practicing nurses in general.
Only nurses from one geographic locale were surveyed.
Also, this was a small study only capable of capturing
large effect sizes. Future studies should utilize larger
sample sizes as well as include participants from mul-
tiple geographic locales, as well as other health profes-
sionals (e.g., bioethicists, psychiatrists, etc.).
The majority of our participants were taking a
graduate-level class on evidence-based nursing, which
may have had an impact on our results. Graduate pro-
grams generally strive to teach research within the con-
text of critical thinking. It is possible that the students in
our sample were more critically minded than the average
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of graduate students [38,39]. However, previous vignette
research [19] examining practicing clinicians’ (not
graduate students) perceptions has found lower credibil-
ity ratings associated with COI.
In conclusion, we find that disclosure of ghostwriting
alone, without other accompanying COI, is sufficient to
lower the perceived credibility of psychiatric research to
an important degree among professional nurses. This
finding is congruent with our previous study finding that
a package of relatively common COI, including ghost-
writing, also lowered the perceived credibility of psychi-
atric research. Moving forward, we suggest that
qualitative research exploring the thought processes be-
hind participants’ ratings and treatment decisions would
be informative.
Additional files
Additional file 1: Vignette 1. Traditional authorship, no ghostwriting.
Additional file 2: Vignette 2. Ghostwriting.
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